(P042) Toxicity and Treatment Outcomes in Single vs Multifractionated Radiotherapy for Acoustic Neuromas

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

FSRT and SRS in treatment for acoustic neuromas had similar outcomes and toxicity at our institution. Both modalities appear to be successful at providing high tumor control with acceptable toxicities in the noninvasive treatment of acoustic neuromas.

Ajaykumar B. Patel, MD, Jennifer L. Peterson, MD, Colleen S. Thomas, MS, Michael G. Heckman, MS, Stephen J. Ko, MD, Katherine S. Tzou, MD, Robert C. Miller, MD, Laura A. Vallow, MD, Steven J. Buskirk, MD; Department of Radiation Oncology, Division of Medical Statistics and Informatics, Mayo Clinic Florida

PURPOSE: To review our institution’s experience in treating acoustic neuromas by comparing toxicity and treatment outcomes using stereotactic radiosurgery (SRS) vs fractionated stereotactic radiation therapy (FSRT).

MATERIALS AND METHODS: A total of 57 consecutive patients were treated with either single-fraction SRS (n = 26) or FSRT (n = 31) for acoustic neuroma at our institution between March 2000 and November 2013. Median dose was 1,200 cGy (range: 1,160–1,600 cGy) for SRS and 2,000 cGy (range: 2,000–2,500 cGy) for FSRT. Data were collected on treatment toxicities and progression in 22 SRS and 29 FSRT patients with sufficient follow-up data. Toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).

RESULTS: Median follow-up length was 39 months in SRS patients and 27 months in FSRT patients. Median maximum tumor dimension for SRS and FSRT was 1.4 cm and 1.6 cm, respectively (P = .097). The most common complication was grade 3 ipsilateral hearing loss, which was experienced in 23% of SRS patients and 35% of FSRT patients. Grade 2 vestibular disorder was experienced in 27% of SRS patients and 21% of FSRT patients. No patient experienced grade ≥ 3 vestibular disorder in either group. Grade 1 and 2 facial nerve toxicity occurred in 14% of SRS patients and 10% of FSRT patients. Grade 1 or 2 trigeminal nerve toxicity occurred in 23% of SRS patients and 10% of FSRT patients. No patient experienced grade ≥ 3 facial nerve or trigeminal nerve toxicity. Only three patients (one in FSRT, two in SRS) had disease progression. At 1, 3, and 5 years after the start of treatment, the cumulative incidence of progression was 0%, 8%, and 8% for SRS patients and 0%, 0%, and 11% for FSRT patients, respectively (P = .47). There was no statistically significant difference in likelihood of any individual type of complication or disease progression between patients treated with SRS or FSRT (all P >.12). There was no evidence of an association with occurrence of different types of complications for maximum tumor dimension, SRS dose, or FSRT dose (all P ≥ .19).

CONCLUSION: FSRT and SRS in treatment for acoustic neuromas had similar outcomes and toxicity at our institution. Both modalities appear to be successful at providing high tumor control with acceptable toxicities in the noninvasive treatment of acoustic neuromas.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content